Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autogenous vaccine against avian metapneumovirus type b
- Development stage
- Unknown
- Lead developer
- Cambridge Technologies
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous, Inguinal Fold, Drinking Water, Spray, Intranasal, Oral
01
Overview
An experimental autogenous vaccine developed through a collaboration between Merck Animal Health and Cambridge Technologies. This vaccine is designed to provide protection against Avian Metapneumovirus (aMPV) type B. It was deployed for emergency field use in the U.S. poultry sector in December 2024 to address immediate needs arising from a recent outbreak.
Beyond the preview
Go deeper on autogenous vaccine against avian metapneumovirus type b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autogenous vaccine against avian metapneumovirus type b.